As expected, RSV challenge following FI-RSV or vvG-immunization induced pulmonary eosinophila; enhanced Th2-type responses such as increased airway and lung secretion levels of IL-4, IL-5, and IL-13; eosinophilic airway inflammation; and development of goblet cell hyperplasia and mucus hyperproduction. This evidence concerns the gene IL13 and inflammation.